Abstract 1685P
Background
Family caregivers play a vital role in cancer care, yet their effective integration, needs assessment, and support in German outpatient settings require further examination. This qualitative study explores family caregivers' experiences, preferences, and integration challenges, employing a unique dyadic approach to analyze patient-caregiver dynamics and incorporating oncologists' perspectives on effective caregiver integration. It also suggests areas of potential integration of innovative technologies to address these challenges.
Methods
The study uses a reflexive thematic analysis of qualitative semi-structured interviews with 15 patient-caregiver dyads involving advanced cancer patients with solid tumours and three oncologists at a German outpatient cancer centre.
Results
Three interconnected themes emerged: 1) The multifaceted impact of illness on patient-caregiver dyads, emphasizing the significance of dyadic support and incongruence; 2) Communication with physicians and understanding of healthcare Information, stressing the need for tailored prognostic communication, and considering health literacy aspects; 3) Navigating healthcare services and psychosocial support, underlining the importance of a regular needs and distress evaluation, providing personalized support in the form of a referral and proactive guidance upon cancer diagnosis.
Conclusions
The study's findings have practical implications for healthcare practice and policy. Healthcare systems should adopt a more caregiver-inclusive approach that provides proactive psychosocial support at the beginning of the cancer journey, and tailored communication with healthcare professionals. This approach could include developing and implementing targeted digital tools that allow automated needs evaluation and incorporation of referrals for specialized support programs for cancer caregivers. The future investigation and implementation of such innovative technologies is important, as they have the potential to reduce the caregiving burden and significantly enhance the overall quality of cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Rose: Other, Institutional, Leadership Role: Head of Promis National Center Germany. All other authors have declared no conflicts of interest.
Resources from the same session
1687P - Perceptions of genetic testing and lived experiences in women with locally advanced or metastatic ovarian cancer: A focus on BRCAm and BRCAwt patients
Presenter: María Jesús Rubio Pérez
Session: Poster session 11
1688P - Psychosocial distress and spirituality among elderly patients with cancer in Nigeria
Presenter: Zainab Ogunjimi
Session: Poster session 11
1689TiP - The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
Presenter: Domenico Galetta
Session: Poster session 11
1692P - A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma
Presenter: Xinan Sheng
Session: Poster session 11
1693P - CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
Presenter: Laurence Albiges
Session: Poster session 11
1695P - Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)
Presenter: Ulka Vaishampayan
Session: Poster session 11
1696P - A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naïve metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results
Presenter: Saby George
Session: Poster session 11
1697P - Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis
Presenter: Sarmad Sadeghi
Session: Poster session 11
1698P - Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
Presenter: Balaji Venugopal
Session: Poster session 11